OmniAb, Inc.OABIEarnings & Financial Report
OmniAb, Inc. is a global biotechnology firm specializing in proprietary transgenic animal platforms and antibody discovery solutions. It partners with pharma and biotech clients to accelerate fully human therapeutic antibody development for oncology, autoimmune diseases and high-need medical areas across key global markets.
OABI Q4 FY2025 Key Financial Metrics
Revenue
$8.4M
Gross Profit
N/A
Operating Profit
$-15.8M
Net Profit
$-14.2M
Gross Margin
N/A
Operating Margin
-188.2%
Net Margin
-169.3%
YoY Growth
-22.5%
EPS
$-0.11
OmniAb, Inc. Q4 FY2025 Financial Summary
OmniAb, Inc. reported revenue of $8.4M (down 22.5% YoY) for Q4 FY2025, with a net profit of $-14.2M (down 8.5% YoY) (-169.3% margin).
Key Financial Metrics
| Total Revenue | $8.4M |
|---|---|
| Net Profit | $-14.2M |
| Gross Margin | N/A |
| Operating Margin | -188.2% |
| Report Period | Q4 FY2025 |
OmniAb, Inc. Annual Revenue by Year
OmniAb, Inc. annual revenue history includes year-by-year totals (for example, 2023 revenue was $34.2M).
OmniAb, Inc. Quarterly Revenue & Net Profit History
OmniAb, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $8.4M | -22.5% | $-14.2M | -169.3% |
| Q4 FY2024 | $10.8M | +124.1% | $-13.1M | -121.0% |
| Q2 FY2024 | $7.6M | +9.6% | $-13.6M | -179.0% |
| Q4 FY2023 | $4.8M | -86.4% | $-14.1M | -291.4% |
| Q3 FY2023 | $5.5M | -20.7% | $-15.7M | -287.3% |
| Q2 FY2023 | $6.9M | -3.5% | $-14.7M | -212.0% |
| Q1 FY2023 | $16.9M | +75.8% | $-6.1M | -36.1% |
| Q4 FY2022 | $35.3M | — | $6.8M | 19.3% |
Income Statement
| Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q2 2024 | Q4 2024 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $35.3M | $16.9M | $6.9M | $5.5M | $4.8M | $7.6M | $10.8M | $8.4M |
| YoY Growth | N/A | 75.8% | -3.5% | -20.7% | -86.4% | 9.6% | 124.1% | -22.5% |
Balance Sheet
| Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q2 2024 | Q4 2024 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $421.2M | $413.0M | $405.2M | $391.7M | $375.2M | $337.3M | $325.6M | $300.9M |
| Liabilities | $79.8M | $72.2M | $71.4M | $67.2M | $60.6M | $43.1M | $37.9M | $33.9M |
| Equity | $341.4M | $340.8M | $333.8M | $324.5M | $314.6M | $294.2M | $287.6M | $267.0M |
Cash Flow
| Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q2 2024 | Q4 2024 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-7.1M | $27.7M | $-10.0M | $-6.2M | $-9.1M | $-12.2M | $-3.9M | $-5.7M |